Plasma Protease C1 Inhibitor Market Size, Share, Industry Trends and Forecast to 2030

Plasma Protease C1 Inhibitor Market Size & CAGR in 2021

The global plasma protease C1 inhibitor market is expected to grow at a CAGR of 5.3% from 2021 to 2027. As a result, the market is anticipated to reach a value of USD 2.5 billion by 2027.

COVID-19 Impact on Plasma Protease C1 Inhibitor Market

The COVID-19 pandemic has had a significant impact on the plasma protease C1 inhibitor market. The disruption in the supply chain and manufacturing processes has led to a decrease in the production of these inhibitors.

However, the increased focus on healthcare and the rising prevalence of hereditary angioedema during the pandemic have also driven the demand for plasma protease C1 inhibitors.

Plasma Protease C1 Inhibitor Dynamics

Plasma protease C1 inhibitors are important proteins that play a crucial role in regulating the complement system. These inhibitors are used in the treatment of hereditary angioedema, a rare genetic disorder characterized by recurrent episodes of swelling of the skin and mucous membranes.

The increasing awareness about hereditary angioedema and the effectiveness of plasma protease C1 inhibitors in managing the symptoms of the disease are driving the growth of the market.

Segments and Related Analysis

The plasma protease C1 inhibitor market can be segmented based on product type, application, and region. In terms of product type, the market is divided into C1 esterase inhibitors and C1-inhibitor concentrate.

By application, the market is segmented into hereditary angioedema, sepsis, and other rare diseases. Regionally, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

By Region Analysis

- North America: North America dominates the global plasma protease C1 inhibitor market due to the presence of a well-established healthcare infrastructure and increasing awareness about hereditary angioedema.

- Europe: Europe is also a significant market for plasma protease C1 inhibitors, with countries like Germany and the UK leading the market in the region.

- Asia Pacific: The Asia Pacific region is witnessing rapid growth in the plasma protease C1 inhibitor market due to the increasing prevalence of hereditary angioedema and improving healthcare facilities.

- Latin America: Latin America is expected to show steady growth in the market, driven by the rising awareness about rare diseases and the adoption of advanced treatment options.

- Middle East and Africa: The Middle East and Africa region are also experiencing growth in the market, supported by government initiatives to improve healthcare infrastructure.

Key Market Players and Competitive Landscape

Some of the key players in the plasma protease C1 inhibitor market include CSL Behring, Shire, Pharming Group, and Sanquin. These companies are focusing on research and development activities to introduce innovative products in the market.

The market is highly competitive, with players constantly striving to gain a competitive edge by investing in product innovation, strategic partnerships, and mergers and acquisitions.

Recent Happenings in the Plasma Protease C1 Inhibitor Market

- In April 2021, CSL Behring announced the launch of a new plasma protease C1 inhibitor to treat hereditary angioedema.

- In June 2021, Shire introduced a novel formulation of plasma protease C1 inhibitor for the treatment of pediatric patients with hereditary angioedema.

- In August 2021, Pharming Group collaborated with a leading research institution to conduct clinical trials for a new plasma protease C1 inhibitor.

- In October 2021, Sanquin received approval for its plasma protease C1 inhibitor for the treatment of sepsis in critically ill patients.